Vir Biotechnology (VIR) Cash from Investing Activities (2018 - 2026)

Vir Biotechnology has reported Cash from Investing Activities for 9 years, with the latest figure at $11.8 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 90.67% year-over-year to $11.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $195.4 million (down 67.31% YoY) and the FY2025 annual result came in at $310.4 million, down 37.85% from the prior year.
• Cash from Investing Activities fell to $11.8 million in Q1 2026 per VIR's latest filing, from $86.7 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $230.3 million in Q2 2023 and troughed at -$662.6 million in Q3 2022.
• A 5-year average of -$12.2 million and a median of $40.4 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities tumbled 997.12% in 2022, then soared 346.23% in 2025.
• Over 5 years, Cash from Investing Activities stood at -$153.1 million in 2022, then surged by 31.56% to -$104.8 million in 2023, then soared by 234.28% to $140.7 million in 2024, then sank by 38.43% to $86.7 million in 2025, then plunged by 86.34% to $11.8 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $11.8 million, $86.7 million, and $40.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.